Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00099970 · ClinicalTrials.gov registry record · Phase 2
Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy
A Phase 2 study of Melanoma and Metastases, sponsored by PDL BioPharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 7
- Study locations
NCT00099970: Completed Phase 2 study of Melanoma and Metastases, sponsored by PDL BioPharma.
NCT00099970 is a Phase 2 study of Melanoma and Metastases that has completed, run by PDL BioPharma. The registered enrollment target is 40 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (94% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00099970, a Phase 2 study of Melanoma and Metastases, has completed, sponsored by PDL BioPharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 7
- Study locations
Study Summary
This clinical trial is being conducted to determine tumor response and preliminary safety of a monoclonal antibody that specifically binds to a cell surface receptor (α5β1 integrin) that is required for the establishment of new blood vessels during tumor growth, a process known as angiogenesis.
Conditions Studied
Interventions
- DRUG M200 (volociximab) in Combination with Dacarbazine (DTIC)
Study Locations (7)
California
- UCLA School of Medicine - Los Angeles
- Cancer Institute Medical Group, Inc. - Santa Monica
Alabama
- University of Alabama at Birmingham-Comprehensive Cancer Ctr. - Birmingham
Arizona
- Arizona Cancer Center - Tucson
Pennsylvania
- University of Pittsburgh - Pittsburgh
South Carolina
- Palmetto Hematology Oncology, P.C. - Spartanburg
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2004-12 |
| Est. Completion | 2006-03 |
| Phase | Phase 2 |
What the finished NCT00099970 record still lists
NCT00099970 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which M200 (volociximab) in Combination with Dacarbazine (DTIC) is the first listed.
NCT00099970 lists 7 locations in 6 states (California, Alabama, Arizona).
Frequently Asked Questions
What is clinical trial NCT00099970 about?
NCT00099970 is a clinical study titled "Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy". This clinical trial is being conducted to determine tumor response and preliminary safety of a monoclonal antibody that specifically binds to a cell surface receptor (α5β1 integrin) that is required for the establishment of new blood vessels during tumor growth, a process known as angiogenesis.
What is the current status of trial NCT00099970?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2004-12. Estimated completion is 2006-03.
What conditions does trial NCT00099970 study?
This clinical trial studies the following conditions: Melanoma, Metastases.
What interventions are being tested in trial NCT00099970?
The interventions under investigation include: M200 (volociximab) in Combination with Dacarbazine (DTIC) (DRUG).
Who is sponsoring clinical trial NCT00099970?
This trial is sponsored by PDL BioPharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00099970 being conducted?
This trial has 7 study locations across Alabama, Arizona, California, Pennsylvania, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00099970's enrollment target sits among peer trials
40 177th of 266 higher than 85 of 266 other Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
RECRUITING · Phase 2
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia